BRIEF—Truxima wins approval in Canada

The Canadian unit of Israeli generics firm Teva Pharmaceutical has been granted approval for its biosimilar product Truxima (rituximab), referencing Rituxan.

Truxima is now the first biosimilar rituximab approved in Canada for the treatment of adults with non-Hodgkin’s lymphoma, chronic lymphocytic leukemia and rheumatoid arthritis.

Truxima won its first approval in 2016, in South Korea, and has since won approvals in Europe and in the USA.